I

Iterative Health

AI-powered polyp detection for colorectal cancer

Vice President – Mergers & Acquisitions

Full-Time
No salary listed
Expert
Bachelor's, Master's, MBA
Cambridge, MA, USA+1 moreMore locations: New York, NY, USA
HybridIn-office collaboration is required two days per week.
Business & StrategyCorporate Strategy

About the job

Requirements
  • Deep M&A expertise and strong healthcare or health-tech experience.
  • 8–10+ years of relevant experience in M&A, corporate development, investment banking, private equity, or a combination of these disciplines; experience in healthcare services, life sciences, or an adjacent multi-site industry is preferred.
  • Significant experience leading and closing complex acquisitions and strategic transactions.
  • Demonstrated experience managing transactions across the full M&A lifecycle, from sourcing through integration.
  • Strong understanding of healthcare, health-tech, life sciences, digital health, healthcare technology, or adjacent markets.
  • Deep knowledge of physician practice management and the financial management of physician practices, including reimbursement systems, metrics, and operational challenges.
  • Exceptional financial modeling, valuation, transaction structuring, and analytical capabilities.
  • Experience presenting transaction recommendations to C-suite executives and/or Boards of Directors.
  • Strong negotiation skills and demonstrated ability to manage sophisticated external advisors and counterparties.
  • Bachelor's degree required.
  • MBA or other advanced degree preferred.
Responsibilities
  • Partner with the Chief Development Officer, executive leadership, and internal and external stakeholders to identify, evaluate, structure, negotiate, and execute acquisitions and other strategic transactions that advance the company's growth strategy.
  • Develop and execute an M&A strategy aligned with company growth priorities and financial objectives.
  • Identify, evaluate, and prioritize acquisition and de novo opportunities across clinical research, healthcare services, life sciences, and adjacent markets.
  • Build a pipeline of acquisition targets through industry relationships, proprietary sourcing, investors, and external advisors.
  • Conduct market mapping and competitive analysis to assess strategic fit, growth potential, and value-creation opportunities.
  • Lead the end-to-end M&A lifecycle, including valuation, financial modeling, due diligence, deal structuring, negotiation, and closing.
  • Coordinate cross-functional due diligence across finance, legal, operations, people, technology, and regulatory functions to identify risks and opportunities.
  • Develop acquisition models, return analyses, pro forma projections, and assessments of synergies, capital requirements, and transaction economics.
  • Partner with internal stakeholders and external advisors to structure transactions, negotiate terms, and manage documentation through closing.
  • Evaluate acquisition and de novo opportunities to expand the clinical research site network and geographic reach.
  • Partner with business and functional leaders to assess operational feasibility, investment requirements, and opportunities for scalable growth.
  • Lead post-acquisition integration planning and translate transaction assumptions into measurable operating priorities and value-creation initiatives.
  • Monitor post-close performance and refine integration processes to maximize transaction value.
  • Establish scalable M&A processes, evaluation frameworks, approval workflows, and pipeline reporting.
  • Present acquisition opportunities, financial analyses, transaction updates, and recommendations to the Chief Development Officer, executive leadership, and Board of Directors, as appropriate.
  • Build relationships with industry executives, investors, founders, and advisors to strengthen deal flow and market intelligence.
  • Mentor and develop corporate development team members as the function scales.
  • Perform related duties as requested.
Desired Qualifications
  • Experience in healthcare services, life sciences, or an adjacent multi-site industry.

About the company

Iterative Health develops and deploys AI-powered tools for gastrointestinal (GI) care. Its main product is SKOUT®, an FDA-cleared device that helps doctors find adenomas (polyps) during GI procedures, supporting clinical judgment rather than replacing it. The company also offers AI-enabled documentation and data standardization technologies to improve the quality of patient care and to streamline clinical trials, enabling consistent reporting across institutions. By combining AI image analysis, data-driven insights, and streamlined research workflows, Iterative Health aims to improve colorectal cancer prevention and diagnosis and to extend high-quality GI care to underserved populations around the world.

Company Size

201-500

Company Stage

Series C

Total Funding

$262.2M

Headquarters

Boston, Massachusetts

Founded

2017

Get referred to Iterative Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 30, 2026 Series C raised $77 million from GV and Intrepid Growth Partners.
  • July 2026 partnerships with GANJ and US Heart & Vascular widened patient access.
  • September 2026 leadership hires, including Dr. Nadege Gunn and Dr. Samin Sharma, sharpen credibility.

What critics are saying

  • Cardiology and obesity expansion now competes against entrenched site networks and academic centers.
  • SKOUT’s 510(k) clearance stays limited to colonoscopy, so product moat remains narrow.
  • If sponsor demand softens, Iterative’s labor-heavy site model strains margins and growth by 2027.

What makes Iterative Health unique

  • Iterative Health combines AI software, centralized operations, and embedded community research sites.
  • SKOUT has FDA clearance for real-time polyp detection during white-light colonoscopy only.
  • The network spans 110-plus sites across GI, hepatology, obesity, and cardiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Vision/Dental/ Medical Insurance
  • Life/Disability Insurance
  • Parental Leave
  • Stock Options
  • Flexible Work Hours
  • Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

-4%
Associated Press
Aug 11th, 2026
Iterative Health appoints Mount Sinai's Dr Samin K. Sharma as honorary chair of interventional cardiology

Iterative Health has appointed Dr Samin K. Sharma as scientific advisor and honorary chair of interventional cardiology. Dr Sharma is director of the Cardiovascular Clinical Institute at Mount Sinai Hospital and director of interventional cardiology at Mount Sinai Health System. Dr Sharma has over 30 years of experience and has authored more than 350 peer-reviewed articles. He pioneered the use of the Rotablator technique for complex coronary blockages. The appointment follows Iterative Health's recent US site network expansion, including acquiring cardiology research sites from NextStage Clinical Research and partnering with US Heart & Vascular. The company's network spans more than 100 sites across three continents in GI, hepatology, obesity, and cardiology research.

Business Wire
Aug 11th, 2026
Iterative Health appoints Dr. Samin K. Sharma at Mount Sinai Hospital as honorary chair of Interventional Cardiology.

Iterative Health appoints Dr. Samin K. Sharma at Mount Sinai Hospital as honorary chair of Interventional Cardiology. CAMBRIDGE, Mass.-(BUSINESS WIRE)-Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the appointment of Samin K. Sharma, MD, FACC, MSCAI, Director of the Cardiovascular Clinical Institute at The Mount Sinai Hospital, as a scientific advisor and honorary chair of Interventional Cardiology. In this role, Dr. Sharma brings best-in-class clinical and scientific leadership from one of the foremost academic medical centers to advance the company's cardiology strategy. "Dr. Sharma is a world-renowned physician recognized for his clinical judgment, commitment to patient-centered care, and contributions to the field," said Jonathan Ng, founder and CEO of Iterative Health. "His experience will help strengthen our therapeutic expertise, protocol and trial design, and scientific publications, ultimately helping our sites move studies forward with the excellence and rigor sponsors expect." Dr. Sharma is director of the S.P. and Seema Lohia Cardiovascular Clinical Institute and director of interventional cardiology at Mount Sinai Health System, where he also serves as president of the Mount Sinai Heart Network. With more than 30 years of experience, he is one of the most awarded cardiologists for his contributions to medical science. He is also credited with pioneering the use of the Rotablator technique for complex, calcified coronary blockages, has authored more than 350 peer-reviewed articles, and sits on the editorial boards of several cardiology journals. Dr. Sharma is passionate about medical education, mentoring fellows and experienced cardiologists alike through innovative teaching methods, including symposiums and live-broadcast cases that reach thousands. "There's a real gap between what a trial protocol asks for and what's actually workable at the bedside, and it can cost a study valuable time," said Dr. Sharma. "Iterative Health has built a research network around closing that gap, and it's an honor to help the company strengthen its impact in advancing cardiology research." The appointment follows Iterative Health's recent US site network expansion, including the acquisition of established cardiology research sites from NextStage Clinical Research and a strategic partnership with US Heart & Vascular. The company's network spans more than 100 high-performing sites across three continents in GI, hepatology, obesity, and cardiology research. About Iterative Health Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes. By combining deep expertise in clinical trials with cutting-edge AI, we empower research teams and study sponsors to expand and expedite access to novel therapeutics for patients in need. The company has headquarters in Cambridge, Massachusetts, and New York, New York. For more information, visit www.iterative.health and follow us on LinkedIn for the latest company updates. Contacts. Media Contact Iterative Health: Andrea Sampson President/CEO, Sampson Public Relations Group [email protected] More News From Iterative Health CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health and Gastroenterology Associates of New Jersey partnered to expand access to GI clinical research in New Jersey... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health announced the acquisition of three cardiology sites from NextStage Clinical Research... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health announced the presentation of updated scientific research at Digestive Disease Week (DDW) 2026...

Associated Press
Jul 8th, 2026
Iterative Health partners with GANJ to expand GI clinical research across New Jersey

Iterative Health has partnered with Gastroenterology Associates of New Jersey (GANJ) to expand clinical research access across New Jersey. The collaboration establishes two research sites in Toms River and Clifton, joining Iterative Health's network of over 110 sites globally. GANJ operates 28 locations across New Jersey with more than 60 healthcare professionals. The partnership integrates clinical research into community GI care, leveraging New Jersey's population of over 9.5 million residents and its ethnic diversity. Iterative Health will serve as GANJ's research partner, combining the practice's clinical expertise with its AI-powered technology and operational model. The collaboration focuses particularly on inflammatory bowel disease, with GANJ recently establishing a Comprehensive IBD Care Centre. Additional research sites are under discussion across GANJ's broader provider network. Iterative Health operates the largest community-embedded research site network in the US for GI, hepatology, obesity, and cardiology clinical development.

Planet First Partners
Jun 30th, 2026
Iterative Health raises $77M Series C to accelerate clinical trials with AI-powered research network

Planet First Partners has invested in Iterative Health, a healthcare technology company focused on accelerating clinical research. The investment follows Iterative Health's recent $77 million Series C funding round led by Intrepid Growth Partners and Google Ventures, with participation from EDBI, a family office, Insight Partners, and Obvious Ventures. Iterative Health operates a clinical research network spanning over 100 sites across North America, Europe, India, and Australia. The company uses AI and centralised operations to improve trial efficiency, achieving twice faster site activation and three times higher patient enrolment compared to industry standards. The Series C funds will support expansion into cardiology and obesity research, building on the company's existing focus on gastroenterology and hepatology. Iterative Health partners with over 40 pharmaceutical, biotech, and CRO organisations.

Business Wire
May 14th, 2026
Iterative Health acquires 3 cardiology sites from NextStage Clinical Research in Texas

Iterative Health, a healthcare technology and services company, has acquired three cardiology research sites in Texas from NextStage Clinical Research. The sites, located in Beaumont, Port Arthur and Waco, bring experienced research teams and established cardiovascular trial operations. The acquisition expands Iterative Health's cardiology footprint as part of its strategy to embed clinical research within community care settings. The company operates over 100 sites across three continents, supported by a 250-person team and proprietary AI tools for patient recruitment and trial design. Cardiovascular disease affects nearly half of US adults, yet clinical trial access remains uneven. The addition strengthens Iterative Health's capabilities across therapeutic areas including gastroenterology, hepatology and obesity, whilst providing patients access to innovative cardiovascular therapies and devices.